IKT Earnings Date & Options Strategy
Inhibikase Therapeutics, Inc. Common Stock
$1.52
November 13, 2026
Earnings TODAY!
Last Updated: September 22, 2026
Pre-Earnings Catalyst Score, Supply-Chain Domino & Conference Radar
Event-Driven Intelligence
Pre-Earnings Catalyst Scanner
Upcoming Radar
IKT is tracked on the upcoming earnings calendar (MONITOR PRE-EARNINGS IV). Watch for options flow acceleration in the 14-day pre-earnings window.
Analyst EPS Revision Momentum
Net Downward Revisions
+0
Up (7D)
+0
Up (30D)
-2
Down (30D)
Curr Qtr Consensus: $-0.09
90D Ago: $-0.09
Supply-Chain Domino & Peer Earnings Read-Through
3 Linked Tickers
DNLI — DNLI
HIGH
Direct ecosystem peer in Drug Design
BIIB — BIIB
HIGH
Direct ecosystem peer in Drug Design
VYGR — VYGR
HIGH
Direct ecosystem peer in Drug Design
Options IV Analysis
Loading IV data...
Earnings Estimates
EPS Estimate (Current Qtr)
$-0.13
EPS Estimate (FY)
$-0.40
Revenue Growth (YoY)
-100.0%
Forward P/E
-3.7x
How to Trade Earnings with Options
Buy Options Strategy
Buy options when IV percentile is below 30. This means options are cheap relative to their historical pricing. As earnings approach, IV typically rises (IV expansion), increasing the value of your options even before earnings.
Sell Premium Strategy
Sell options when IV percentile is above 70. After earnings, IV crashes (IV crush), which benefits option sellers. Iron condors and credit spreads profit from this IV collapse.
Timing Tips
- 2-3 weeks before: Best time to buy options if IV is low
- 1 week before: IV starts rising, still okay to buy if IV < 50th percentile
- Day of earnings: IV at peak - avoid buying, consider selling
- After earnings: IV crushes 30-50%, sellers profit
Gamma Positioning
Loading gamma data...
Analyst Ratings
STRONG BUY
2 analysts
Price Target
$8.00
Strong Buy
Buy
Hold
Sell
More IKT Analysis
Company Info
Company
Inhibikase Therapeutics, Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology